These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 32050968

  • 1. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
    Shao SC, Chang KC, Lin SJ, Chien RN, Hung MJ, Chan YY, Kao Yang YH, Lai EC.
    Cardiovasc Diabetol; 2020 Feb 12; 19(1):17. PubMed ID: 32050968
    [Abstract] [Full Text] [Related]

  • 2. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
    Feng X, Gu Q, Gao G, Yuan L, Li Q, Zhang Y.
    Ann Endocrinol (Paris); 2020 Oct 12; 81(5):476-481. PubMed ID: 32822653
    [Abstract] [Full Text] [Related]

  • 3. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.
    Diabetes Obes Metab; 2019 Aug 12; 21(8):1925-1934. PubMed ID: 31050099
    [Abstract] [Full Text] [Related]

  • 4. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY, Cho Y, Lee M, Kim YJ, Lee YH, Lee BW, Cha BS, Kang ES.
    Diabetes Metab J; 2019 Apr 12; 43(2):158-173. PubMed ID: 30688052
    [Abstract] [Full Text] [Related]

  • 5. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
    Min SH, Yoon JH, Moon SJ, Hahn S, Cho YM.
    Sci Rep; 2018 Mar 13; 8(1):4466. PubMed ID: 29535389
    [Abstract] [Full Text] [Related]

  • 6. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F, Kumashiro N, Fuchigami A, Hirose T.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):86. PubMed ID: 29895330
    [Abstract] [Full Text] [Related]

  • 7. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
    Kusunoki M, Natsume Y, Miyata T, Tsutsumi K, Oshida Y.
    Drug Res (Stuttg); 2018 Dec 12; 68(12):704-709. PubMed ID: 29966149
    [Abstract] [Full Text] [Related]

  • 8. Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease.
    Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, Khunti K.
    Diabetes Obes Metab; 2022 Nov 12; 24(11):2138-2147. PubMed ID: 35676798
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):1. PubMed ID: 31910850
    [Abstract] [Full Text] [Related]

  • 10. Body weight change associated kidney outcomes of sodium-glucose cotransporter new users.
    Jimba T, Kaneko H, Azegami T, Suzuki Y, Okada A, Ko T, Fujiu K, Takeda N, Morita H, Hayashi K, Nishiyama A, Node K, Yasunaga H, Takeda N, Nangaku M, Komuro I.
    Diabetes Obes Metab; 2024 Oct 07; 26(10):4535-4543. PubMed ID: 39072974
    [Abstract] [Full Text] [Related]

  • 11. Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus.
    Suzuki Y, Kaneko H, Okada A, Ohno R, Yokota I, Fujiu K, Jo T, Takeda N, Morita H, Node K, Yasunaga H, Komuro I.
    J Endocrinol Invest; 2024 May 07; 47(5):1261-1270. PubMed ID: 38114769
    [Abstract] [Full Text] [Related]

  • 12. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS.
    Kidney Int; 2018 Jan 07; 93(1):231-244. PubMed ID: 28860019
    [Abstract] [Full Text] [Related]

  • 13. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
    Shimizu N, Ogawa A, Hayashi A, Shichiri M.
    J Diabetes Complications; 2022 Jul 07; 36(7):108225. PubMed ID: 35690574
    [Abstract] [Full Text] [Related]

  • 14. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
    Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V.
    Diabetes Obes Metab; 2019 Feb 07; 21(2):340-348. PubMed ID: 30207040
    [Abstract] [Full Text] [Related]

  • 15. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
    Mamza J, Mehta R, Donnelly R, Idris I.
    Diabetes Technol Ther; 2016 Feb 07; 18(2):85-92. PubMed ID: 26752504
    [Abstract] [Full Text] [Related]

  • 16. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 07; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 17. Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    Chung MC, Hung PH, Hsiao PJ, Wu LY, Chang CH, Wu MJ, Shieh JJ, Chung CJ.
    JAMA Netw Open; 2021 Nov 01; 4(11):e2135353. PubMed ID: 34797368
    [Abstract] [Full Text] [Related]

  • 18. Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis.
    Savarese G, D'Amore C, Federici M, De Martino F, Dellegrottaglie S, Marciano C, Ferrazzano F, Losco T, Lund LH, Trimarco B, Rosano GM, Perrone-Filardi P.
    Int J Cardiol; 2016 Oct 01; 220():595-601. PubMed ID: 27390996
    [Abstract] [Full Text] [Related]

  • 19. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M, Peng X, Geremakis C, Bae J.
    J Manag Care Spec Pharm; 2015 Dec 01; 21(12):1204-12. PubMed ID: 26679969
    [Abstract] [Full Text] [Related]

  • 20. Comparative effects of sulphonylureas, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors added to metformin monotherapy: a propensity-score matched cohort study in UK primary care.
    Wilkinson S, Williamson E, Pokrajac A, Fogarty D, Stirnadel-Farrant H, Smeeth L, Douglas IJ, Tomlinson LA.
    Diabetes Obes Metab; 2020 May 01; 22(5):847-856. PubMed ID: 31957254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.